Teladoc: Why I'm Long This Inflection Stock
Teladoc Health, Inc. is currently undervalued, trading at 11x forward free cash flow, presenting a compelling investment opportunity despite its dire outlook. The company's strength lies in its scalable virtual healthcare services, with a focus on chronic condition management and international expansion. Stabilizing revenue growth rates to around 1% in 2025 is crucial for Teladoc's valuation and future prospects.
Teladoc Stock Rises 59.4% in Three Months: Is This Your Buy Signal?
TDOC's use of machine learning and AI continues to drive healthcare innovation.
Teladoc: Maybe This Goose Isn't Cooked Yet (Rating Upgrade)
Teladoc Health, Inc.'s telehealth model struggles with low utilization despite its potential, leading to consistent operating losses and a declining average revenue per member. New CEO Chuck Divita aims to revitalize Teladoc by enhancing value propositions, cutting costs, and potentially selling or restructuring the Better Help segment. Teladoc's survival hinges on cost-cutting, maintaining integrated care clients, and resolving Better Help's profitability issues, with a cautious outlook for 2025.
Teladoc Enhances Virtual Sitter With AI for Improved Care Delivery
TDOC's upgraded Virtual Sitter uses AI to prevent patient falls, boost staff efficiency and enhance care delivery, thus addressing major challenges in hospitals and health systems.
If You'd Invested $10,000 in Teladoc Stock 5 Years Ago, Here's How Much You'd Have Today
Spoiler: The news isn't pretty.
Every Teladoc Investor Should Keep an Eye on This Number
Hint: You won't find it on the top or bottom lines.
Teladoc Health, Inc. (TDOC) Q3 2024 Earnings Call Transcript
Teladoc Health, Inc. (NYSE:TDOC ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Michael Minchak - Head of Investor Relations Chuck Divita - Chief Executive Officer Mala Murthy - Chief Financial Officer Conference Call Participants Stephanie Davis - Barclays Lisa Gill - JPMorgan Jessica Tassan - Piper Sandler Michael Cherny - Leerink Partners Sean Dodge - RBC Capital Markets Sarah James - Cantor Fitzgerald Jailendra Singh - Truist Securities Richard Close - Cannacord Glen Santangelo - Jefferies Charles Rhyee - TD Cowen Allen Lutz - Bank of America Sameer Patel - Evercore ISI Operator Hello, and welcome to the Teladoc Health Third Quarter 2024 Call. My name is Alex, and I'll be coordinating the call today.
Teladoc (TDOC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teladoc (TDOC) Reports Q3 Loss, Tops Revenue Estimates
Teladoc (TDOC) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.35 per share a year ago.
Exploring Analyst Estimates for Teladoc (TDOC) Q3 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Teladoc (TDOC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
